Truist Securities Upgrades Edwards Lifesciences to Buy, Raises Price Target to $113
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsUpgradesPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.
Truist Securities analyst Richard Newitter upgrades Edwards Lifesciences (NYSE:EW) from Hold to Buy and raises the price target from $95 to $113.
